Innate Pharma SA (IPHYF) Income Statement
Innate Pharma SA Income Statement
Last quarter (Q2 2026), Innate Pharma SA's total revenue was $3.12M, a decrease of 74.77% from the same quarter last year. In Q2, Innate Pharma SA's net income was $-19.62M. See Innate Pharma SA’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 2.79M | $ 12.62M | $ 51.90M | $ 49.64M | $ 12.11M | |
| $ 2.79M | $ -31.86M | $ 5.62M | $ 6.01M | $ -34.89M | |
| $ 56.21M | $ 19.72M | $ 18.29M | $ 63.44M | $ 25.52M | |
| Depreciation and Amortization | $ 1.38M | $ 1.99M | $ 5.09M | $ 4.42M | $ 4.60M |
| $ -55.97M | $ -50.99M | $ -1.84M | $ -61.30M | $ -43.23M | |
| $ -57.36M | $ -51.58M | $ -12.67M | $ -24.63M | $ -47.83M | |
| $ 1.98M | $ 2.10M | $ 5.10M | $ -547.00K | $ 2.35M | |
| $ -55.38M | $ -56.96M | $ -7.57M | $ -57.97M | $ -45.48M | |
| $ -49.18M | $ -49.47M | $ -7.57M | $ -58.10M | $ -52.81M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.55 | $ -0.61 | $ -0.09 | $ -0.73 | $ -0.74 |
| Diluted EPS | $ -0.55 | $ -0.61 | $ -0.09 | $ -0.73 | $ -0.66 |
| Weighted Average Shares Outstanding | 89.41M | 60.93M | 60.93M | 60.93M | 60.93M |
| Weighted Average Shares Outstanding (Diluted) | 89.41M | 81.05M | 80.45M | 79.64M | 79.54M |
Currency in EUR